Lexicon Pharmaceuticals (NASDAQ: LXRX) — Company Overview, News & Financial Data
Lexicon Pharmaceuticals is a biopharmaceutical company developing treatments for diabetes and metabolic disorders.
Lexicon Pharmaceuticals
Lexicon Pharmaceuticals (NASDAQ:LXRX) is a biopharmaceutical company dedicated to discovering, developing, and commercializing innovative treatments for patients with diseases that are often overlooked or inadequately treated by existing therapies. Its operations span from the early-stage research and development of new drug candidates to the clinical trials necessary for regulatory approval. One of Lexicon's significant projects includes advancing treatments for diabetes, heart failure, and other metabolic disorders, aiming to address unmet medical needs and improve patient outcomes. The company's objectives involve pushing the boundaries of medical research to bring transformative therapies to the market, ensuring these innovations are accessible to the patients who need them most.
Snapshot
Operations
Products and/or services of Lexicon Pharmaceuticals
- XERMELO (telotristat ethyl), an orally-delivered small molecule drug for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy.
- Sotagliflozin, an investigational oral dual inhibitor of SGLT1 and SGLT2, aimed at treating heart failure and diabetes.
- LX9211, a development-stage small molecule inhibiting AAK1 to potentially address neuropathic pain.
- LX2761, a preclinical compound working as an SGLT1 inhibitor for diabetes but remains localized in the gastrointestinal tract.
- Research on the role of SGLT inhibitors in renal and cardiovascular diseases, examining the broader therapeutic potential of these treatments.
- Advancements in the understanding and application of small molecule drugs, focusing on novel treatments for chronic diseases.
Lexicon Pharmaceuticals executive team
- Michael S. ExtonCEO & Director
- Scott M. CoianteSenior VP & CFO
- Brian T. CrumSenior VP, General Counsel & Secretary
- Wendy E. McDermottSenior Vice President of Human Resources
- Craig B. GranowitzSenior VP & Chief Medical Officer
- Kristen L. AlexanderVice President of Finance & Accounting
- Lisa M. DeFrancescoSenior Vice President of Investor Relations & Corporate Communications
- Suma GopinathanSenior Vice President of Discovery
- Rachel Yap MartensSenior VP & Chief Commercial Officer
Latest news about Lexicon Pharmaceuticals
Key financials
Reported results for Lexicon Pharmaceuticals, in USD.
- Market cap
- 649.6M
- Revenue (TTM)
- 41.5M
- P/E ratio
- —
- EPS (diluted, TTM)
- -0.2
- Dividend yield
- —
- Profit margin
- -147.4%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 49.8M | -48.9M | -50.3M | |
| 31.1M | -197.1M | -200.4M | |
| 1.2M | -171.8M | -177.1M | |
| 139K | -100.8M | -101.9M |